Browse drugs

…by TNG260 sensitizes STK11-mutant tumors to anti-PD1 treatment. TNG260, in combination with pembrolizumab, is being evaluated in a pha…

…minantly stereotactic radiosurgery (SRS)) followed by continued osimertinib, with encouraging PFS/OS and acceptable toxicity. By contrast, …

…re treated with vaccine on days 1 and 8 of a 3 week cycle, with pembrolizumab given on day 1 of each cycle. Patients in Arm A (n=30) received…

…ssion quartiles in a subgroup of patients with CRC treated with pembrolizumab (n=500). The CXCR4high cohort showed significantly improved sur…

…and poor prognosis. Adding immune checkpoint inhibitors such as pembrolizumab to neoadjuvant chemotherapy has improved pathological response …

…t saving of €11,000 per patient when using Nivolumab instead of Pembrolizumab, with equivalent efficacy. This finding supports a review of pr…

…ortal outcome) as a suspected ADR of different ICIs (nivolumab, pembrolizumab and nivolumab+ipilimumab) within 2 months in the regional Pharm…

… preliminary efficacy, pharmacokinetics and pharmacodynamics of W0180, both as monotherapy and in combination with pembrolizumab (an …

… due to malignant neoplasm progression; none were attributed to ASP9801. One patient in Group B combination safety cohort achieved conf…

…BTC were enrolled from five centers in China. Patients received pembrolizumab (200 mg, every 3 weeks), lenvatinib (8 or 12 mg daily), and mod…

…proach. We report the primary results of a neoadjuvant study of lenvatinib plus pembrolizumab in resectable MCC.Methods In this single-cen…

…9 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…